• ADAM-17: a novel therapeutic target for triple negative breast cancer.

      McGowan, P M; Mullooly, M; Caiazza, F; Sukor, S; Madden, S F; Maguire, A A; Pierce, A; McDermott, E W; Crown, J; O'Donovan, N; et al. (2013-02)
      Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.